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The mitogen-activated kinases JNK1/2/3 are key
enzymes in signaling modules that transduce and
integrate extracellular stimuli into coordinated
cellular response. Here, we report the discovery of
irreversible inhibitors of JNK1/2/3. We describe two
JNK3 cocrystal structures at 2.60 and 2.97 A˚ resolu-
tion that show the compounds form covalent bonds
with a conserved cysteine residue. JNK-IN-8 is
a selective JNK inhibitor that inhibits phosphoryla-
tion of c-Jun, a direct substrate of JNK, in cells
exposed to submicromolar drug in a manner that
depends on covalent modification of the conserved
cysteine residue. Extensive biochemical, cellular,
and pathway-based profiling establish the selec-
tivity of JNK-IN-8 for JNK and suggests that the
compound will be broadly useful as a pharmacolog-
ical probe of JNK-dependent signal transduction.
Potential lead compounds have also been identified
for kinases, including IRAK1, PIK3C3, PIP4K2C,
and PIP5K3.
INTRODUCTION
In mammalian cells the MAPK signaling system is comprised of
at least four distinct signaling modules defined by a core of
MAP4K, MAP3K, MAP2K, and MAPKs that are named after
the ‘‘terminal’’ MAPK in each pathway: ERK1/2, JNK1/2/3,
p38a/b, and ERK5 (Chang and Karin, 2001; Johnson and Lapa-140 Chemistry & Biology 19, 140–154, January 27, 2012 ª2012 Elsevdat, 2002; Pearson et al., 2001; Raman et al., 2007). JNKs (c-jun
NH2-terminal kinase) become highly activated after cells are
exposed to stress conditions such as cytokines, osmotic stress,
hypoxia, and UV light, and are poorly activated by exposure to
growth factors or mitogens (De´rijard et al., 1994; Pulverer et al.,
1991). There are three distinct alternatively spliced genes
(Jnk1, Jnk2, and Jnk3) that produce approximately ten different
proteins. The predominant isoforms JNK1 and JNK2 are ubiqui-
tously expressed, but JNK3 is expressed primarily in the
nervous system (De´rijard et al., 1994; Kallunki et al., 1994; Sluss
et al., 1994; Mohit et al., 1995). JNKs are activated by phos-
phorylation in the activation T loop at residues Thr183/Tyr185
by the MAP2Ks MKK4 and MKK7, and are deactivated by
MAPK phosphatases including MKP1 and MKP5. Signaling
through the JNK pathway is organized via binding to ‘‘scaf-
folding’’ proteins such as JIP that assemble signaling
complexes containing MAP3K, MAP2K, and MAPKs in addition
to JNK-phosphorylated transcription factors such as c-Jun,
ATF2, and Elk1.
Because JNKs comprise a central node in the inflammatory
signaling network, it is not surprising that hyperactivation of
JNK signaling is a very common finding in a number of disease
states, including cancer and inflammatory and neurodegenera-
tive diseases. A significant body of genetic and pharmacolog-
ical evidence suggests that inhibitors of JNK signaling may
provide a promising therapeutic strategy: JNK3 knockout
mice exhibit amelioration of neurodegeneration in animal
models of Parkinson and Alzheimer’s disease (Kyriakis and
Avruch, 2001; Zhang and Zhang, 2005; Hunot et al., 2004).
JNK1 phosphorylates IRS-1, a key molecule in the insulin-
sensing pathway that downregulates insulin signaling, and
JNK1 knockout mice are resistant to diet-induced obesity
(Aguirre et al., 2000, 2002; Hirosumi et al., 2002; Sabio andier Ltd All rights reserved
Figure 1. Chemical Structures for JNK Inhibitors
(A) Representative JNK inhibitors.
(B) Structural modifications relative to JNK-IN-1 for JNK-IN-1–JNK-IN-6 or relative to JNK-IN-7 for JNK-IN-7–JNK-IN-12 are highlighted in red.
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Discovery of Selective Covalent Inhibitors of JNKDavis, 2010); JNK2, often in concert with JNK1, has been
implicated in the pathology of autoimmune disorders such as
rheumatoid arthritis (Han et al., 2002) and asthma (Wong,
2005; Pelaia et al., 2005; Blease et al., 2003; Chialda et al.,
2005). A recent study suggests that JNK2 may also play a
role in vascular disease and atherosclerosis (Osto et al.,
2008). However, to date, and to our knowledge, no inhibitors
of JNK have been approved for use in humans.
Numerous small molecules from a variety of scaffolds such as
indazoles, aminopyrazoles, aminopyridines, pyridine carboxa-
mides, benzothien-2-ylamides and benzothiazol-2-yl acetoni-
triles, quinoline derivatives, and aminopyrimidines have been
reported to act as selective ATP-competitive JNK inhibitors
(LoGrasso and Kamenecka, 2008). Despite this plethora of
compounds, many exhibit poor kinase selectivity and/or do not
inhibit the phosphorylation of well-characterized substrates of
JNK in cells. For example, one of the earliest and still most widely
used inhibitors is the anthrapyrazolone, SP-600125 (Bennett
et al., 2001; Figure 1A), which exhibits exceptionally low speci-
ficity for JNK (Bain et al., 2007) and should only be used in combi-
nation with other tools to rule out a potential role for JNK in
a particular process (In˜esta-Vaquera et al., 2010). Other reported
JNK inhibitors such as AS601245 (Gaillard et al., 2005) only
inhibit c-Jun phosphorylation at high concentrations, which is
likely due to a combination of limited cell penetration, ATPChemistry & Biology 19, 140concentration, and differences between biochemical and
cellular sensitivities to JNK inhibitors.
To address these challenges, we sought to use structure-
based drug design to develop ATP site-directed covalent
inhibitors of JNKs that would target a unique cysteine conserved
in all the JNKs. Cysteine-directed covalent inhibitors possess
a number of potential advantages relative to noncovalent inhib-
itors such as an ability to control kinase selectivity using both
noncovalent and covalent recognition of the kinase and the
ability to exhibit prolonged pharmacodynamics despite compe-
tition with high endogenous intracellular ATP concentrations.
Selective cysteine-directed covalent inhibitors have been devel-
oped for a number of kinases including Rsk (FMK) (Cohen et al.,
2005; Nguyen, 2008), FGFRs (FIIN-1) (Zhou et al., 2010), Mek
(Schirmer et al., 2006), Nek2 (Henise and Taunton, 2011), and
other kinases possessing a cysteine immediately proceeding
the ‘‘DFG motif’’ (hypothemycin and analogs) as well as several
undergoing clinical investigation as inhibitors of EGFR (HKI-
272, BIBW2992, CI1033, EKB569) and BTK (AVL-292,
PCI32765) (Singh et al., 2010). Despite these efforts, to our
knowledge, only 4 different cysteine positions have been tar-
geted in the ATP site to date, even though at least 180 kinases
possess a cysteine that could theoretically be targeted by suit-
ably designed inhibitors (Zhang et al., 2009). Here, we report
the structure-based design, detailed biochemical and cellular–154, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 141
Table 1. JNK Inhibitor Potency In Vitro and In Vivo
IC50 CEnuJ-c-p)Mn( 50 (nM) 
JNK1 JNK2 JNK3 HeLa A375
JNK-IN-1 7,780 4,230 7,750 ND ND
JNK-IN-2 809 1,140 709 704 2,400 
JNK-IN-3 >10,000 >10,000 >10,000 ND ND
JNK-IN-4 2,390 5,460 7,220 ND ND
JNK-IN-5 2.11 1.93 0.96 118 32
JNK-IN-6 ND ND 148 6,760 1,905 
JNK-IN-7 1.54 1.99 0.75 130 244 
JNK-IN-8 4.67 18.7 0.98 486 338 
JNK-IN-9 ND ND 0.50 104 117 
JNK-IN-10 ND ND 0.50 173 141 
JNK-IN-11 1.34 0.50 0.50 48 8.6 
JNK-IN-12 13 11.3 11.0 605 134 
5A 10,000a ND 200a >10,000 >10,000 
SP-600125 ND 110a 190a 7,450 1,985 
AS601245 150a 220a 70a 2,025 2,400 
Biochemical IC50 in nanomolar for JNK inhibitors against JNK1/2/3 and cellular EC50 for inhibition of c-Jun phosphorylation in HeLa and A375 cells.
Brown highlight indicates IC50 < 100 nM; EC50 < 500 nM; and red highlight, 100 nM< IC50 < 200 nM; 500 nM<EC50 < 1000 nM.ND, not determined. See
also Table S1.
aValues for reference inhibitors 5A (Angell et al., 2007), SP-600125 (Bennett et al., 2001), and AS601245 (Gaillard et al., 2005) are from the literature.
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by covalent inhibitors that can irreversibly modify a conserved
cysteine residue in JNK.
RESULTS
Serendipitous Discovery and Rational Optimization
of a Covalent JNK Inhibitor
Most currently reported cysteine-directed covalent inhibitors are
from the ‘‘type 1’’ (Liu andGray, 2006) inhibitor class: they bind to
the kinase in an ‘‘active’’ conformation with the activation loop in
a conformation conducive to substrate binding. We speculated
whether ‘‘type 2’’ inhibitors that bind kinases in an ‘‘inactive’’
state with the activation loop in a conformation that blocks
substrate from binding might also present a promising platform
from which to design a new class of covalent inhibitors. Through
an examination of kinases cocrystallized with type 2 inhibitors,
we noticed that both c-Kit and PDGFR possess a cysteine
immediately preceding the DFG motif that marks the beginning
of the activation loop and that might be exploited by a suitably
designed type 2 inhibitor. We decided to use the phenylamino-
pyrimidine core of imatinib as a scaffold for elaboration because
this compound binds Abl, c-Kit, and PDGFR in the type 2 confor-
mation, and because it possesses favorable drug properties.
Measurement of the distance between the methylpiperazine
moiety of imatinib and Cys788 in c-Kit (PDB 1T46; Mol et al.,
2004) inspired us to replace the methylpiperazine moiety with
an electrophilic acrylamide bearing a water solubility-enhancing
dimethylamino group to generate JNK-IN-1 (Figure 1B). The
kinase selectivity of JNK-IN-1 was profiled at a concentration
of 10 mMagainst a 400 kinase panel using KINOMEscanmethod-
ology where, to our surprise, it exhibited significant binding to142 Chemistry & Biology 19, 140–154, January 27, 2012 ª2012 ElsevJNK1/2/3 in addition to the expected imatinib targets of Abl,
c-kit, and DDR1/2 (see Table S1 available online). These binding
results were confirmed by measuring IC50 for the inhibition of
JNK activity using Z0-LYTE assay format (Table 1). This result
was unanticipated because despite the large number of JNK
inhibitors reported in the literature, to our knowledge, there are
no reports of type 2 JNK inhibitors, and we, therefore, did not
anticipate that imatinib could bind to JNK in an extended type
2 conformation. However, there are a number of structurally
related phenylaminopyrimidines such as 9L (Kamenecka et al.,
2010) and 30 (Alam et al., 2007; Figure 1A) that bind to JNK
in a type 1 conformation, and we speculated that perhaps
JNK-IN-1 was binding in an analogous fashion to JNK. In addi-
tion we hypothesized that imatinib might exploit an alternative
type 1 conformation when binding to JNK where the inhibitor
assumes a U-shaped configuration, as has been observed in
a Syk-imatinib costructure (PDB 1XBB; Atwell et al., 2004). If
JNK-IN-1 were to recognize JNK analogously to how imatinib
binds to Syk, the acrylamide moiety of JNK-IN-1 would be
placed within covalent bond-forming distance of Cys116 of
JNK1 and JNK2 and Cys154 of JNK3.
To test these hypotheses, a number of analogs of JNK-IN-1
were prepared (Figure 1B). First, the ‘‘flag methyl’’ was removed
from JNK-IN-1 to yield JNK-IN-2 because this methyl group is
a key driver of selectivity for imatinib to c-kit, Abl, and PDGF rela-
tive to a number of other kinases (Zimmermann et al., 1996). We
also expected JNK-IN-2 to be better able to assume the
U-conformation relative to the extended type 2 conformation
and thereby increase noncovalent recognition of the JNK ATP-
binding site. As shown in Table 1, JNK-IN-2 indeed possessed
a 5- to 10-fold improved IC50 for inhibition of JNK1/2/3 kinase
activity relative to JNK-IN-1. This encouraged us to obtain directier Ltd All rights reserved
Figure 2. Mass Spectra for THZ-IN-2 Labeled JNK1 Protein
(A) Untreated JNK1 protein.
(B) JNK-IN-2 treated recombinantly produced JNK1 kinase domain. Inset mass spectra were obtained after deconvolution and show addition of 493 daltons after
incubation with JNK-IN-2.
(C) HCD tandemmass spectrometry of the peptide LMDANLC*QVIQME (JNK residues 110–122; C* indicates labeled cysteine). Identification of ions of type b and
y are indicated with lines above and below the sequence, respectively. See also Figure S2.
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Upon incubation of recombinantly produced JNK1 with JNK-
IN-2 (5-fold excess), electrospray mass spectrometry revealedChemistry & Biology 19, 140that the intact mass of the protein increased by the expected
493 daltons (Figures 2A and 2B), consistent with the covalent
addition of one molecule of JNK-IN-2 to the kinase. Subsequent–154, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 143
Figure 3. Crystal Structure of Complex JNK-IN-2 and JNK-IN-7 with JNK3
Crystal structures of JNK3 residues 39–402 modified at Cys-154 by (A) JNK-IN-2 and (B) JNK-IN-7. The covalent inhibitors (green stick figure for JNK-IN-2 and
orange stick figure for JNK-IN-7) and the key residues of JNK3 that are involved in hydrophobic and hydrogen bonding interactions with the covalent inhibitors are
labeled and are shown in stick models (gray). The hydrogen bonds between the kinase hinge residue Met-149 and the aminopyrimidine motif of the covalent
inhibitors are represented as orange dotted lines (Figure S3). See also Figures S1 and S4.
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etry analysis identified a peptide (residues LMDANLCQVIQME)
modified by JNK-IN-2 at Cys 116 as predicted by the molecular
modeling (Figure 2C).
Despite the confirmation of JNK-IN-2 as a cysteine-directed
JNK inhibitor, the approximately 1.0 mM IC50 suggests a relatively
inefficient labeling of the kinase during the biochemical assay.
The molecular modeling of JNK-IN-2 with JNK3 suggested that
the amino pyrimidine motif would form the typical bidentate
hydrogen bonding interaction with Met149 in the kinase ‘‘hinge’’
segment, whereas the pyridine substituent was situated toward
the back of the ATP pocket adjacent to the gatekeeper Met146
and possibly making a hydrogen bond between the pyridine N
and the side-chain amino group of Lys93. Although the acryl-
amide of JNK-IN-2 was within covalent bond-forming distance
of Cys154, the geometry based on the modeling did not appear
to be ideal for facilitating nucleophilic addition of the cysteine
thiol (Figure S1A). To investigate the functional importance of
a potential hydrogen bond between Met149 and JNK-IN-2, the
aniline NH was changed to an ether linkage in JNK-IN-3. As
expected, this change resulted in more than 100-fold increase
in biochemical IC50 against JNK1. Next, we explored various
changes that might place the acrylamide in a more optimal posi-
tion for reaction with Cys116 in JNK1. We first attempted to
insert an additional methylene spacer in JNK-IN-4, which unfor-
tunately, increased the IC50 against JNK1 by 3-fold. We investi-
gated different regioisomers of the 1,3-dianiline and 1,4-benza-
mide moieties of JNK-IN-2. The most dramatic improvement in
IC50 was observed when 1,4-dianiline and 1,3-benzamide were
incorporated as the linker segment between the pyrimidine
and the acrylamide moiety, as exemplified by JNK-IN-5 and
JNK-IN-7. These compounds possessed a dramatic 500-fold
lower IC50 against JNK1, 2, and 3 when compared with
JNK-IN-2. Molecular docking of JNK-IN-7 with JNK3 suggested
that this improvement in potency was likely due to a more
optimal placement of the acrylamide relative to Cys154, which
may result inmore efficient covalent bond formation (Figure S1B).
Incubation of JNK-IN-7 and JNK3 followed by electrospray144 Chemistry & Biology 19, 140–154, January 27, 2012 ª2012 Elsevmass spectrometry revealed the addition of a single molecule
of inhibitor to the protein and labeling of Cys154 (Figure S2).
To investigate the importance of covalent bond formation to
the potency of this class of inhibitor, we prepared JNK-IN-6
with an unreactive and approximately isosteric propyl amide
group replacing the acrylamide of JNK-IN-5. As expected, this
compound exhibited an almost 100-fold less potent biochemical
IC50 on JNK1, 2, and 3 (Table 1). We then prepared a small
collection of analogs of JNK-IN-7 bearing modifications ex-
pected to influence its selectivity relative to other kinases.
We prepared three methylated analogs, JNK-IN-8, JNK-IN-9,
and JNK-IN-10, all of which retained the ability to potently inhibit
JNK biochemical activity. We replaced the pyridine ring of JNK-
IN-7 with substituents that had previously been described for
other JNK inhibitors, including a bulky group 2-phenylpyrazolo
[1,5-a]pyridine (Alam et al., 2007) and benzothiazol-2-yl acetoni-
trile (Gaillard et al., 2005). The influence of these changes on
kinase selectivity is discussed in detail below.
Cocrystal Structure of JNK-IN-2 and JNK-IN-7
with JNK3
In order to validate the molecular modeling results and to
provide a basis for further structure-based optimization efforts,
we cocrystallized JNK-IN-2 and JNK-IN-7 with JNK3 de novo
using the same JNK3 protein reported previously for 9L (Kame-
necka et al., 2010; Figures 3 and S3A). The resulting 2.60 and
2.97 A˚ crystal structures were in good agreement with the dock-
ing model described above. Continuous electron density was
visible to Cys154 consistent with covalent bond formation (Fig-
ure S3B). The inhibitor formed three hydrogen bonds with
JNK3, two from the aminopyrimidine motif to the kinase hinge
residues Leu148 and Met149, and a third from the amide NH
to Asn152. This third hydrogen bond may be important for posi-
tioning the terminal ring and orienting the acrylamide moiety
proximal to Cys154, thereby facilitating covalent bond formation.
The overall kinase conformation of JNK is remarkably similar to
the reported 9L crystal structure (average rmsd 2.40 A˚; Kame-
necka et al., 2010) with the kinase assuming an activeier Ltd All rights reserved
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not appear to trap an unusual conformation of the kinase. There
is a small hydrophobic pocket adjacent to the aniline ortho posi-
tion that may explain why tolerance exists for the ‘‘flag’’ methyl
group in JNK-IN-8, a group that also provided a crucial selec-
tivity determinant. The pyridine moiety binds in a hydrophobic
pocket and did not optimally fill this space, which was consistent
with the potency improvements realized by replacing it with the
larger moieties present in JNK-IN-11 and JNK-IN-12. Further
modification of the inhibitor in this region would clearly afford
significant opportunities for modulating both inhibitor potency
and selectivity.
Inhibition of Cellular c-Jun Phosphorylation
In parallel with biochemical evaluation, we investigated the
ability of the compounds to inhibit JNK activity in cells using
two independent assay formats. This is a critical issue because
there are several reported JNK inhibitors with nanomolar
biochemical potency that translate intomicromolar cellular inhib-
itors. The best-characterized direct phosphorylation substrate of
JNK is the transcription factor c-Jun. The first assay format is
a high-throughput screening (HTS) compatible cellular assay
capable of measuring changes in phosphorylation of c-Jun using
the measurement of time-resolved fluorescence resonance
energy transfer (TR-FRET) between a stably expressed GFP-
c-Jun (1–79) fusion protein and a terbium-labeled anti pSer73
c-Jun antibody as readout (Robers et al., 2008; Carlson et al.,
2009; Stebbins et al., 2008). The second assay format consisted
of treating serum-starved A375 cells with test compounds
followed by stimulation of the JNK pathway with anisomycin
andmonitoring c-Jun phosphorylation by single-cell microscopy
using an anti-phospho Ser73 antibody (Millard et al., 2011). With
the exception of a few compounds, both assay formats provided
a similar rank order of potency for this compound series (Table
1). In agreement with the biochemical assays, JNK-IN-5 also
provided the breakthrough in cellular potency and was capable
of inhibiting c-Jun phosphorylation with an IC50 of 100 nM in
HeLa cells and 30 nM in A375 cells. Introduction of the methy-
lene dimethylamine group to yield JNK-IN-7 resulted in a 2- to
3-fold loss in potency for cellular JNK inhibition, which was not
predicted based upon the enzymatic assay. Introduction of
methyl groups at the ortho-position of the dianiline ring or to the
meta and ortho positions of the benzamide resulted in
compounds with cellular potency in the hundreds of nanomolar
range. JNK-IN-11, the most potent cellular inhibitor of JNK
activity in this series, incorporated the phenylpyrazolo[1,5-a]pyri-
dinemotif andpossessed an IC50 of30and10nM inHeLa and
A375 cells, respectively. JNK-IN-6, the compound incapable of
covalent bond formation, possessed an IC50 50-fold higher
than its covalent analog JNK-IN-5, once again underscoring the
requirement for the acrylamide moiety to achieve potent cellular
inhibition. To allow direct comparison with published JNK inhib-
itors, we tested SP600125, 5A (Angell et al., 2007), and
AS601245 in parallel in both assay formats. All these compounds
exhibited IC50 values in the micromolar range, which suggests
that covalent inhibition may be required to observe potent JNK
inhibition at least under the conditions investigated.
In order to evaluate the kinetics with which JNK-IN-5 could
covalently modify JNK in cells, we developed a pulse-chaseChemistry & Biology 19, 140assay. A375 cells were treated with JNK-IN-5 for 1–5 hr to allow
for cell penetration and labeling of intracellular targets. Cell
lysates were then prepared and labeled with ATP-biotin, which
contains a reactive acyl phosphate anhydride that reacts
nonspecifically with the catalytic lysine of kinases including
JNK (Patricelli et al., 2007). Streptavidin affinity chromatography
was then used to isolate all biotinylated proteins, and JNK
protein was detected following SDS-PAGE and western blotting
(Figure S4A). The length of the JNK-IN-5 incubation time
required to fully protect JNK from subsequent labeling by ATP-
biotin provides a measure of the rate of intracellular covalent
bond formation. Three hours were required for JNK-IN-5 to
modify JNK to background levels by this assay. As a negative
control, the noncovalent inhibitor JNK-IN-6 was subject to the
same protocol and was demonstrated to be incapable of pro-
tecting JNK from labeling by ATP-biotin. The kinetics of covalent
binding between the JNK-IN-5 and JNK3 in vitro was also inves-
tigated in a similar way. JNK-IN-5 was capable of completely
labeling JNK3 in 45 min when introduced at a 27 M excess
(Figure S4B).
Cellular Kinase Specificity of Covalent JNK Inhibitors
The kinase selectivity of several key compounds was first evalu-
ated using a chemical proteomic approach, KiNativ, which is
capable of monitoring 200 kinases in A375 cells (ActivX Biosci-
ences). To probe the intracellular targets of the compounds,
we incubated A375 cells with the inhibitors and then looked for
protection of labeling by an ATP-biotin probe that labels
conserved lysines on kinases and other nucleotide-dependent
enzymes. This provided an important advantage relative to the
in vitro kinase selectivity profiling because in vitro the short
incubation times and presence of reactive thiols in the buffers
can potentially cause false-negatives for acrylamide-modified
kinase inhibitors. Treatment of A375 cells with 1 mM of four of
the irreversible JNK inhibitors resulted in the identification of
JNK as themost potent and common target (Table 2). In contrast
the reversible inhibitor JNK-IN-6 did not inhibit JNK activity in
the same live-cell treatment. In addition to JNK 1, 2, 3, JNK-
IN-7 also bound to IRAK1, PIK3C3, PIP5K3, and PIP4K2C.
Because cysteine-directed covalent kinase inhibitors will some-
times cross-react with kinases that contain an equivalently
placed cysteine, we performed a sequence alignment to identify
all kinases that have a cysteine near JNK1 Cys116 (Table S2).
Among the 40 kinases revealed through this analysis, only
IRAK1 exhibited a detectable binding affinity to JNK-IN-7 based
upon KINOMEscan profiling. Because an IRAK1 crystal structure
is not available, we examined the IRAK4 crystal structure (PDB
3CGF). This showed that Cys276 is potentially situated in
a similar location relative to the reactive Cys154 of JNK3. Thus,
covalent modification of IRAK1 by JNK-IN-7 is a possibility,
and subsequent biochemical kinase assay revealed an IC50 of
10 nM against IRAK1. To evaluate whether IRAK1 is a bona
fide intracellular target of JNK-IN-7, we also asked whether the
compound could inhibit the E3-ligase activity of pellino, which
provides an indirect measure of inhibition of IRAK1 kinase
activity in cells. JNK-IN-7 inhibited interleukin-1-stimulated
Pellino 1 E3 ligase activity but required a relatively high concen-
tration of 10 mM to achieve complete inhibition (P. Cohen,
personal communication). Sequence alignments did not reveal–154, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 145
Table 2. Cellular Kinase Profiling with KiNativ Technology
Kinase
Family Kinase Labeling Site JNK-IN-6 JNK-IN-7 JNK-IN-8 JNK-IN-11 JNK-IN-12 
JNK1, JNK2, JNK3 Lys2 27.3 99.7 98.7 99.8 98.6 
2syLa83p 32.6 16.4 13.2 95.9 –28
rehtOa83p 12.4 14.7 3.9 98.9 –13.8 
2syLA3KSG 6.8 20.4 10.6 40.7 –7.7 
2syLB3KSG 23.6 12.3 –8.5 67.1 –29.6 
PFTAIRE1 Lys1 –6 75.3 38.1 12.8 25.7 
CMCG
2syL9KDC 7.6 16.6 –34.1 –23.4 –35.3 
ROCK1 Other 24.4 –11.9 10 –8.2 –97AGC ROCK1, ROCK2 Lys2 11.6 –21.5 –17.1 –33.9 –91
PTA3K5PIP 16.8 91.8 18.7 99.3 –11.4 
PIK3C3 ATP 26.5 77.5 18.1 8.9 7.5 
PIK3C3 ATP 3.1 74.2 6.4 –11 –0.5 
PIP4K2C ATP –4.7 77.2 1.9 –4.4 43.9 
PIP4K2C ATP 35.7 84.3 32.2 24.3 42.6 
DNAPK ATP 51.1 17.4 34.9 23.3 –65.4 
DNAPK ATP 31.7 18.4 10.5 –9.4 –80.7 
Lipid 
PTA1KPTI 27 –0.2 24.6 –0.7 8.6 
1syL2DKP 12 13.6 4.9 40.9 –79
1syL1DKP 28.7 2 8.6 29.4 –21.6 
PKD1, PKD2 Lys2 15.9 18.2 –3 10.4 –39.3 
MARK1 Lys2 23.9 7.9 8.9 18.6 –43.5 
MARK2 Lys1 13.4 23.6 9.6 20.8 –41.1 
MARK2, MARK3 Lys2 22.9 26.5 13.9 0.4 –38.7 
MARK3 Lys1 –7.3 –13.5 –12 –27.8 –67.9 
CAMK
1syL2gKHP 28 –7 –0.8 –76 –94.1 
2syLa1KC 19.5 –20.2 –13.6 61.1 –96CK1 CK1d, CK1e Lys2 32.4 8.4 –21.8 88.4 –75
2syLAruA 9.9 20.9 –8 68.2 –23
AurA, AurB, AurC ATP Loop 4.9 19.1 –11.3 53.8 –20.9 
2syLaKKI 27.3 –9.2 4.9 –7.3 –79.2 Others
2syLbKKI 33.4 –10.1 –6.5 –11.2 –97.5 
ZC2/TNIK, ZC3/MINK Lys2 52.8 31 45.1 75.9 –36.2 
ZC1/HGK, ZC2/TNIK, 
 ZC3/MINK Lys2 8.8 8.3 –11.3 65.1 –25.5 
ZC2/TNIK Lys1 –15.9 20.9 9.9 >80 –8.9 
2syL2OAT 22.5 –3.7 –21.6 42.6 –13
MAP2K1, MAP2K2 Lys2 24.3 3.2 3.2 –10.4 –3.7 
STE
TAO1, TAO3 Lys2 35.8 13.1 2.9 34.1 –10.8 
TK ABL, ARG Lys1 –1.4 1.9 –2.7 56.1 7.9 
2syL1KARI –4.6 81 0.8 5.4 –14.9 
1syLKAZ 3 15.5 –7.8 84.4 –40.2 
2syLFARB 8.9 7 –23.7 27.8 6.2 TKL
2syL1FAR –20.2 –7.3 –41.4 25.5 8.6 
Percent inhibition (color coded as indicated in the legend) of kinase labeling by ATP-biotin that results from incubating A375 cells with the inhibitors for
3 hr at a concentration of 1 mM is indicated (larger numbers indicate stronger binding to the kinase). Brown highlight indicates >90% inhibition; red
highlight, 75%–90% inhibition; orange highlight, 50%–75% inhibition; and green highlight, no change. See also Table S2.
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in PIK3C3, PIP4K2C, and PIP5K3, but further work will be
required to evaluate whether these are indeed functional targets
of JNK-IN-7.
Although JNK-IN-7 is a relatively selective JNK inhibitor in
cells, introduction of the flag methyl to yield JNK-IN-8 resulted
in a dramatic improvement in selectivity and eliminated binding
to IRAK1, PIK3C3, PIP4K2C, and PIP5K3. The dramatic selec-
tivity improvement that results from introduction of this flag
methyl group has been previously reported for imatinib (Zim-
mermann et al., 1996). Replacement of the pyridine ring with146 Chemistry & Biology 19, 140–154, January 27, 2012 ª2012 Elsevbulkier substituents as exhibited by JNK-IN-11 resulted in
a broadening of the selectivity profile as well as further
enhancing the potency for inhibition of c-Jun phosphorylation
in cells. JNK-IN-11 binds potently to JNKs, p38, PIP5K3, ZAK,
ZC2, PIP5K3, and CK1, demonstrating that this compound
class might be a valuable lead compound to develop selective
inhibitors of these potential alternative targets. In contrast to
pyridine in JNK-IN-7, a benzothiazol-2-yl acetonitrile moiety in
JNK-IN-12 resulted in enhanced specificity, demonstrating the
potential to modulate selectivity by the choice of functionality
in this region.ier Ltd All rights reserved
Table 3. JNK Inhibitor Potency on Potential Off-Targets
21-NI-KNJ11-NI-KNJ8-NI-KNJ7-NI-KNJ
Kinase IC50 (nM) (Enzymatic) Kinase
IC50 (nM) 
(Enzymatic) Kinase
IC50 (nM) 
(Enzymatic) Kinase
IC50 (nM) 
(Enzymatic) 
JNK1 1.5 JNK1 4.7 JNK1 1.3 JNK1 13
JNK2 2 JNK2 18.7 JNK2 0.5 JNK2 11.3 
JNK3 0.7 JNK3 1 JNK3 0.5 JNK3 11
IRAK1 14.1 MNK2 238 EGFR(L861Q) 21 IRAK1 37.6 
KIT 2,410 FMS 287 EGFR(L858R) 24.9 HIPK4 57.1 
HIPK1 5,010 HIPK4 8,970 DDR1 56.1 AKT2 89.9 
KIT >10,000 CSNK1E 82.9 AKT1 >370 Kinase Kd (nM) (KINOMEscan) MET(M250T) >10,000 CSNK1G2 161 AKT3 >370 
YSK4 4.8 PDGFRB >10,000 PDGFRB 1,030 SLK 884 
ERK3 22 PRKX 7,500 KIT 1,320   
RIOK2 30 Kinase Kd (nM) (KINOMEscan) Kinase
Kd (nM) 
(KINOMEscan) Kinase
Kd (nM) 
(KINOMEscan) 
PIP5K2C 32 KIT(V559D) 92 EGFR(G719C) 2.6 KIT(V559D,T670I) 160 
CDKL5 34 KIT(V559D,T670I) 56 EGFR(E746-A750del) 7   
KIT(L576P) 40 MYLK4 4,000 KIT(V559D) 8.2   
KIT(V559D) 48 RIOK2 120 PFCDPK1 14   
ICK 54   DMPK2 18   
DRAK1 100   CIT 95   
DYRK2 120   ERBB2 230   
BIKE 190   PRKD3 240   
Enzymatic IC50 or KD for the potential additional kinase targets. For JNK-IN-7 and JNK-IN-11 the kinases with the score below 5 were tested, and for
JNK-IN-8 and JNK-IN-12, kinases with score below 1 were tested (see profiling in Table S1). Sky blue highlight indicates IC50 < 50 nM; turquoise high-
light, 50 nM < IC50 < 100 nM; KD < 50 nM; and aqua highlight, 100 nM < IC50 < 200 nM, 50 nM < KD < 100 nM. See also Tables S1 and S3.
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To complement the KiNativ profiling, the in vitro kinase selectivity
of several key compounds was evaluated comprehensively
by using two complementary approaches: kinase-binding
assays against a panel of 442 distinct kinases using with the
KINOMEscan methodology (DiscoveRx), and standard radioac-
tivity-based enzymatic assays against a panel of 121 kinases
(The National Centre for Protein Kinase Profiling in Dundee).
Based upon the KINOMEscan results, JNK-IN-7, JNK-IN-8,
and JNK-IN-12 possessed highly selective S (ten) scores
(defined as the ratio number of kinases inhibited by more than
90% at screening concentration of 1 mM) of 0.085, 0.031, and
0.025, respectively (Table S1). For example, JNK-IN-7 exhibited
binding inhibition of 95% or more to approximately 14 kinases at
the concentration of 1.0 mM. We attempted to confirm all these
potent binding targets using either an enzymatic kinase assay
or through the measurement of a dissociation constant (KD) to
the kinase in question. JNK-IN-7 was confirmed to have a KD
or IC50 of 100 nM or less against eight additional kinases
(Table 3). JNK-IN-7 was next tested for its ability to inhibit the
enzymatic activity of a panel of 121 kinases at a concentration
of 1.0 mM. This analysis revealed 12 kinases that were inhibited
more than 80% relative to the DMSO control, and follow-up
IC50 determination revealed sub-200 nM IC50 against of IRAK1,
ERK8, and NUAK1 (Table S3). JNK-IN-12 bearing a benzothia-
zol-2-yl acetonitrile in place of the pyridine conferred an
improved selectivity relative to JNK-IN-7. The KINOMEscan
score for JNK-IN-12 was even smaller than JNK-IN-8, and
follow-up enzymatic assays on the potent targets revealed IC50
values of 37.6, 57.1, and 89.9 nM for IRAK1, HIPK4, and AKT2,
respectively (Table 3). The introduction of phenylpyrazolo[1,5-
a]pyridine to JNK-IN-11 resulted in a significant decrease in
kinase selectivity as assessed by KINOMEscan (score = 0.125)Chemistry & Biology 19, 140and more than 30 additional kinases including different mutants
of EGFR, c-Kit, DDR1, and Gsk3b (Tables 3 and S3). Consistent
with the KiNativ profiling, JNK-IN-8 also exhibited exceptional
selectivity based upon KINOMEscan and enzymatic profiling.
Further biochemical and binding assays failed to identify any
target with an IC50 or KD of less than 1.0 mM. Cumulatively, these
combined profiling technologies demonstrate that both JNK-
IN-8 and JNK-IN-12 are remarkably selective covalent JNK
inhibitors and are appropriate for interrogating JNK-dependent
biological phenomena.
Cellular Pathway Profiling
The profiling above provides an assessment of direct engage-
ment with potential targets but does not address further pertur-
bations that may be induced as a consequence of these binding
events. We, therefore, established a microscopy-based assay
using phospho-specific antibodies selective for c-Jun phosphor-
ylation, and also sentinel nodes in other signaling pathways such
as Erk, p38, JNK, Akt, Stat, NF-kB, and Rsk (Millard et al., 2011;
Figure S5). JNK-IN-7, JNK-IN-8, and JNK-IN-12 exhibited only
on-pathway activity as monitored by inhibition of c-Jun phos-
phorylation. JNK-IN-11 was the only compound found to have
off-pathway activity as exemplified by its ability to potently block
phosphorylation of Erk1/2, Rsk1, Msk1, and p38. This finding is
consistent with the substantially broadened kinase selectivity
profile of this compound. However, JNK-IN-11 also provided
the most complete inhibition of c-Jun phosphorylation, a result
we interpret as reflecting the ability of the compound to inhibit
additional kinases involved in phosphorylation of c-Jun.
To corroborate these data, we also examined the ability of the
compounds to inhibit phosphorylation of JNK, c-Jun, MSK1, and
p38 in HEK293-ILR1 cells following stimulation by anisomycin by
traditional western blotting (Figure 4). All compounds, except the–154, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 147
Figure 4. Cellular Pathway Profiling with Western Blot
Western blot analysis of inhibition of JNK, cJun, MSK1, and p38 for JNK-IN-7 (A), JNK-IN-8 (B), and JNK-IN-11 (C) following anisomycin stimulation of HEK293-
IL1R cells. See also Figures S5 and S6.
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without blocking phosphorylation of MSK1 and p38. The inhibi-
tion was not reversed by removal of JNK-IN-8 from cell culture
medium (Figure S6). The results are in good agreement with
the relative compound potencies established using the immuno-
staining and kinase profiling approaches. A distinct reduction in
electrophoretic mobility shift assay of JNK protein is apparent
upon incubation with the inhibitors presumably as a conse-
quence of covalent modification by the inhibitors. This serves
as a simple means to measure kinase modification.
Evaluation of the Functional Selectivity
To investigate the extent to which the observed cellular effects
resulted from direct covalent modification of JNK1/2/3 cysteine
residues versus other potential intracellular targets, we used
mutagenesis to engineer a Cys to Ser mutant into JNK2.We puri-
fied Cys116Ser JNK2 and confirmed that activated wild-type
JNK2 and mutant JNK2[Cys116Ser] displayed similar KM and
Vmax toward the ATF2 peptide substrate in vitro (Figure 5A). In
the presence of inhibitors, the mutation resulted in a 10-fold
increase in IC50 for inhibition of JNK activity by JNK-IN-11, and148 Chemistry & Biology 19, 140–154, January 27, 2012 ª2012 Elsevremarkably, at least a 100-fold increase in IC50 for JNK-IN-7
and JNK-IN-8 (Figure 5B). Thus, JNK-IN-7 and JNK-IN-8 require
Cys116 for JNK2 inhibition. Overall, our results demonstrate that
JNK-IN-8 is an efficient, specific, and irreversible intracellular
inhibitor of JNK activity by a mechanism that depends on modi-
fication of a conserved cysteine in the ATP-binding motif.
DISCUSSION
The JNK family of kinases constitutes a central node in the
stress-activated MAPK signaling pathway and has been pro-
posed to include drug targets with potential utility in the
treatment of cancer, chronic inflammation, and neurological
disorders. However, with the exception of a recently developed
9L analog (Crocker et al., 2011), achieving pharmacological
inhibition of JNK has been hampered by the lack of potent
and selective inhibitors with suitable pharmacokinetic properties
for use in proof of concept studies in cells and animals. To
address these issues, we have pursued the development of irre-
versible JNK inhibitors that covalently modify a cysteine residue
conserved among JNK family members. The major advantage ofier Ltd All rights reserved
Figure 5. Evaluation of the Functional Selectivity with Mutagenesis
Mutation of the conserved Cys116 to Ser increases the IC50 for inhibition of
JNK2 by over 100-fold for JNK-IN-7 and JNK-IN-8 but only by approximately
10-fold for JNK-IN-11.
(A) KM for substrate ATF for JNK2 wild-type and JNK2[Cys116Ser].
(B) Inhibition of JNK2 kinase activity by JNK2 wild-type and JNK2[Cys116Ser]
by JNK-IN-7, JNK-IN-8, and JNK-IN-11.
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tion can be achieved with only transient exposure of the target
to the inhibitor, which reduces the need to sustain drug concen-
tration at a level sufficient to achieve complete target inhibition
(Singh et al., 2010). From the perspective of preclinical research,
engineered JNKs lacking the cysteine residue (e.g., JNK C116S)
that is modified by covalent inhibitors are drug resistant, poten-
tially making it possible to rigorously establish the selectivity
of the compounds and, thus, the JNK dependency of various
cellular phenotypes.
Our starting point for development of a potent JNK inhibitor
was JNK-IN-1, which is an acrylamide-modified phenylamino-
pyrimidine containing the imatinib backbone that we serendip-
itously discovered to be capable of binding to JNK based on
kinome-wide specificity profiling (Fabian et al., 2005; Goldstein
et al., 2008). Recently, a similar scaffold was used to develop
the first covalent inhibitor of c-Kit, a kinase that possesses
a reactive cysteine residue immediately preceding the DFG
motif of the activation loop (Leproult et al., 2011). Molecular
docking of JNK-IN-2 into the crystal structures of JNK3
provided a rational basis for structure-guided design of the
appropriate linker element that would serve to connect the phe-
nylaminopyrimidine pharmacophore, which is predicted to bind
to the kinase-hinge region of the protein with a reactive acryl-
amide moiety. We discovered that the most critical feature forChemistry & Biology 19, 140potent inhibition of JNK in vitro and in cellular assay inhibition
was for the linker element to contain a 1,4-disposition of the
dianiline moiety and a 1,3-disposition of the terminal aminoben-
zoic acid moiety; these features are exemplified by JNK-IN-7
and JNK-IN-8. A 2.97 A˚ costructure between JNK-IN-7 and
JNK3 showed that our design goals had been made and
demonstrated that a covalent bond is indeed formed with
residue Cys154 of JNK3.
Extensive biochemical and cellular selectivity profiling allowed
us to identify several additional potential kinase targets for JNK-
IN-7, including IRAK1, MPSK1, NEK9, PIK3C3, PIP4K2C, and
PIP5K3. Efficient inhibition of these targets appears to require
an acrylamide moiety because they are not inhibited by JNK-
IN-6, which lacks the acrylamide group. With the exception of
IRAK1, these kinases do not appear to contain a potentially reac-
tive cysteine located in a position analogous to Cys154 on JNK3,
suggesting that in binding to MPSK1, NEK9, PIK3C3, PIP4K2C,
and PIP5K3, JNK-IN-7 may adopt a different conformation than
in binding to JNK3, thereby allowing it to access alternative
cysteine residues. Alternatively, JNK-IN-7 may form covalent
adducts with reactive lysine residues. For example the natural
product Wortmannin undergoes a Michael addition reaction
with Lys833 of PI3K, albeit one that involves a nonacrylamide
electrophilic moiety. We have validated that JNK-IN-7 can
indeed inhibit IRAK-1 dependent E3 ligase activity of pellino,
a protein that functions in the Toll receptor signaling pathway
in cells at relative high compound concentrations (1–10 mM)
(P. Cohen, personal communication). Further compound optimi-
zation guided by cell-based assay will be required to establish if
more potent cellular inhibition of IRAK-1 can be achieved. We
have also initiated chemical and biological experiments to opti-
mize and characterize the potential of compounds such as
JNK-IN-11 to inhibit IRAK1, PIK3C3, PIP4K2C, and PIP5K3 in
a cellular context. With respect to JNKs, we discovered two
ways to further enhance the kinase selectivity of JNK-IN-7. The
first was to introduce an ortho-methyl group (creating JNK-
IN-8), which is analogous to the so-called flag methyl group
of imatinib or the ortho-methoxy group of the ALK inhibitor
TAE684 (Galkin et al., 2007) and of the polo-kinase inhibitor
BI-2356 (Kothe et al., 2007). The crystal structure of JNK-IN-7
predicts that the ortho-methyl group may nestle into a small
grove along the hinge segment between Asp150 and Ala151 of
JNK3. The second was to replace the pyridine moiety with
a geometrically more complex benzothiazol-2-yl acetonitrile
moiety, which was previously shown to represent a favorable
pharmacophore for binding to the JNK ATP site (Gaillard
et al., 2005); JNK-IN-12 carries this modification. This portion
of the inhibitor is predicted to bind in proximity to the ‘‘gate-
keeper’’ methionine and provides a critical selectivity determi-
nant for the compound. In contrast, JNK-IN-11, which contains
a large 2-phenylpyrazolo[1,5-a]pyridine group, displays a
dramatically broadened inhibition profile in both purified
enzyme and cellular assays. JNK-IN-8 and JNK-IN-12 appear
to be the most optimal compounds that balance good potency
and favorable kinase selectivity profiles. JNK-IN-7 and
JNK-IN-11 appear to possess additional targets based upon
the KiNativ profiling, and these compounds may serve as valu-
able ‘‘lead compounds’’ to optimize activity against new
targets. Our selectivity profiling to date has been limited to–154, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 149
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also react with other cysteine-containing enzymes, many of
which have been cataloged in a recent chemoproteomics study
(Weerapana et al., 2010).
Implications for Design of Covalent Kinase Inhibitors
Covalent inhibitors are typically designed by rational modifica-
tion of scaffolds that are already potent noncovalent binders of
the desired target protein. For example the anilinoquinazoline
scaffold provided a template for development of highly potent
covalent and noncovalent inhibitors of EGFR kinase (Smaill
et al., 2000). An alternative approach is to start from relatively
low-affinity noncovalent binders and to allow covalent bond
formation to drive potency toward the desired target. For
example the pyrrolopyrimidine Rsk inhibitor FMK (Cohen et al.,
2005) and the anilinopyrimidine T790M EGFR inhibitor WZ-
4002 (Zhou et al., 2009) both increase approximately 100-fold
in potency for their respective targets as a consequence of cova-
lent bond formation. The covalent inhibitors described in this
study fall into this second category in that they require covalent
bond formation to achieve potent inhibition of JNK activity. One
major advantage of this second approach is that it is much easier
to identify a relatively selective low-affinity noncovalent scaffold
as a starting point relative to a selective high-affinity scaffold.
However, the challenge is that one must identify a scaffold that
allows presentation of the electrophile to the kinase with a
geometry that allows for efficient covalent bond formation. This
is especially true because the residence time for a low-affinity
noncovalent compound is typically very short. As can be seen
from the structure-activity relationship for JNK-IN-1–JNK-IN-
12, relatively minor changes can have dramatic consequences
for the potency of inhibition. This is in sharp contrast to the
general notion that a covalent inhibitor will always be exception-
ally potent. Intracellularly, there is a kinetic competition for modi-
fication of the desired target versus ‘‘off-targets,’’ which may be
other proteins or engagement of cellular pathways that metabo-
lize reactive electrophiles. In addition, proteins are continuously
synthesized and degraded with varying kinetics that can allow
for regeneration of unmodified protein. Therefore, an effective
covalent inhibitor must label its target protein rapidly relative to
competing labeling events and protein turnover.
We have pursued two general approaches to developing
potent covalent kinase inhibitors. The first is to generate small,
rationally designed libraries of electrophile-modified inhibitors
that can be used in cell-based screens to select for compounds
with activity against the desired target. Simple molecular
modeling based on known ATP-site recognition modes can be
used to select where on the scaffold to introduce an electrophilic
group. This approach was used to develop WZ-4002, a potent
and selective inhibitor of the T790M gatekeeper mutation of
EGFR. The disadvantage of this approach is that it requires
considerable up-front synthetic effort, and the cell-based
screening approach requires a relatively high potency for inhibi-
tion to be assayable. The second approach is to search among
a larger set of known kinase inhibitor scaffolds lacking electro-
philes for low-affinity compounds using a biochemical screening
approach that allows for screening at high concentrations and
then using structure-based drug design to prepare a small library
of covalent inhibitors for optimization. The advantage of this150 Chemistry & Biology 19, 140–154, January 27, 2012 ª2012 Elsevapproach is that there exist large collections of known kinase
inhibitors having established kinase selectivity profiles; the
disadvantage is that it can be difficult to predict which scaffolds
will be permissive for the correct trajectory for the electrophile
relative to the protein nucleophile. Our discovery of JNK-IN-1
as a compound that would enable the second approach was
serendipitous, but inspection of published Ambit kinase selec-
tivity data for imatinib (Karaman et al., 2008) shows that the
scaffold had already been annotated as having the ability to
bind to JNK noncovalently. We, therefore, anticipate that it will
be possible to create an efficient pipeline for generation of
first-in-class covalent inhibitors that target the large number of
kinases containing suitably positioned cysteine (and possibly
also lysine) residues.
Our study demonstrates that the KiNativ profiling method-
ology is a powerful tool for discovering and guiding the optimiza-
tion of new covalent inhibitors. First, it allows for an unbiased
screen of the majority of available ATP-competitive targets in
a cellular system of choice. As discussed above, this enables
serendipitous discovery of potential new targets for known
compounds. Second, by assessing selectivity in a cellular
context, the native kinase conformation is accessed, and the
structure-activity relationships appear to correlate well with
functional cellular assays. We anticipate that creation of publicly
accessible kinase selectivity profiles for large sets of compounds
will further enable the search for low-affinity leads for new
kinases of interest.
Use of JNK-IN-8 for Studying JNK Activities in Cellular
Assays
With respect to enabling analysis of JNK signaling pathways in
cells, we have shown that JNK-IN-8 and JNK-IN-11 achieve
potent and relatively selective, covalent inhibition of JNK1-3
kinases in cells. We recommend the use of JNK-IN-8 and JNK-
IN-12 at concentration of approximately 1.0 mM, and we antici-
pate that transfection of cells with drug-resistant cysteine to
serinemutations will make it possible to demonstrate compound
selectivity for various cellular phenotypes. Because kinase inhi-
bition appears to reach completion after approximately 3 hr (Fig-
ure S4A), we recommend preincubating cells with compound for
3 hr prior to analyzing JNK activity. A distinct change in the
electrophoretic mobility shift assay of JNK is observed after
exposure to inhibitor (Figures 4 and S6) thatmay serve as a useful
pharmacodynamic marker of JNK inhibition.
SIGNIFICANCE
The JNK family of protein kinases is a key transducer of
extracellular stress signals, and inhibition of JNK function
may provide a therapeutic strategy to treat a variety of
disorders, including neurodegeneration, cancer, and auto-
immune diseases. Here, to our knowledge, we report the
discovery and characterization of the first irreversible JNK
inhibitors that form a covalent bond with a conserved
cysteine. Compounds such as JNK-IN-8 and JNK-IN-12 are
extremely potent inhibitors of enzymatic and cellular JNK
inhibition as monitored by inhibition of c-Jun, a well-charac-
terized direct phosphorylation substrate. Extensive bio-
chemical and cellular profiling has been performed toier Ltd All rights reserved
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JNK activity. The superior potency and selectivity of JNK-
IN-8 and JNK-IN-12 relative to other previously reported
JNK inhibitors suggest that these compounds will likely
serve as very useful pharmacological probes of JNK-depen-
dent cellular phenomena.
EXPERIMENTAL PROCEDURES
Chemistry
All solvents and reagents were used as obtained. 1H-NMR spectra were
recorded with a Varian Inova 600 NMR spectrometer and referenced to dime-
thylsulfoxide. Chemical shifts are expressed in ppm. Mass spectra were
measuredwithWatersMicromass ZQ using an ESI source coupled to aWaters
2525 HPLC system operating in reverse mode with aWaters Sunfire C18 5 mm,
4.6 3 50 mm column. Purification of compounds was performed with either
a Teledyne ISCO CombiFlash Rf system or a Waters Micromass ZQ prepara-
tive system. The purity was analyzed on an aforementioned Waters LC-MS
Symmetry (C18 column, 4.6 3 50 mm, 5 mM) using a gradient of 5%–95%
methanol in water containing 0.05% trifluoroacetic acid (TFA). Detailed
synthetic schemes and characterization data are presented in the Supple-
mental Experimental Procedures.
JNK1/2/3-Specific Assay Condition (Cascade format)
MAPK8 (JNK1)
The 23 MAPK8 (JNK1)/inactive MAPKAPK3/Ser/Thr 04 Peptide Mixture is
prepared in 50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM
EGTA, 2 mM DTT. The final 10 ml kinase reaction consists of 3.3–13.3 ng
MAPK8 (JNK1), 20 ng inactive MAPKAPK3, and 2 mM Ser/Thr 04 Peptide in
50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and
1 mM DTT. After the 1 hr kinase reaction incubation, 5 ml of a 1:1,024 dilution
of development reagent A is added.
MAPK9 (JNK2)
The 23 MAPK9 (JNK2)/inactive MAPKAPK3/Ser/Thr 04 peptide mixture is
prepared in 50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM
EGTA, 2 mM DTT. The final 10 ml kinase reaction consists of 2.4–9.8 ng
MAPK9 (JNK2), 20 ng inactive MAPKAPK3, and 2 mM Ser/Thr 04 peptide in
50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and
1 mM DTT. After 1 hr kinase reaction incubation, 5 ml of a 1:1,024 dilution of
development reagent A is added.
MAPK10 (JNK3)
The 23 MAPK10 (JNK3)/inactive MAPKAPK3/Ser/Thr 04 peptide mixture is
prepared in 50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM
EGTA, 2 mM DTT. The final 10 ml kinase reaction consists of 1.3–5.3 ng
MAPK10 (JNK3), 20 ng inactive MAPKAPK3, and 2 mM Ser/Thr 04 peptide in
50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and
1 mM DTT. After the 1 hr kinase reaction incubation, 5 ml of a 1:1,024 dilution of
development reagent A is added. The protocol for this assay is available from
http://tools.invitrogen.com/downloads/CustomerProtocol_AssayConditions.pdf.
Intact Protein Analysis
For each analysis, 100 pmol JNK protein with or without inhibitor (JNK-IN-2
or JNK-IN-7) was injected onto a self-packed reverse-phase column (1/32
in outer diameter 3 500 mm inner diameter, 5 cm of POROS 10R2 resin).
After desalting, protein was eluted with an HPLC gradient (0%–100% B in
4 min, A = 0.2 M acetic acid in water, B = 0.2 M acetic acid in acetonitrile,
flow rate = 10 ml/min) into a QTRAP mass spectrometer (AB SCIEX, Toronto)
or an LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose,
CA, USA). The QTRAP was operated in Q1 MS mode at unit resolution
scanning at 2,000 amu/s. LTQ OrbitrapMS spectra were acquired in centroid
mode using the electron multipliers for ion detection. Mass spectra were
deconvoluted using MagTran1.03b2 software (Zhang and Marshall, 1998).
Protease Digestion and Nano-Liquid Chromatography/Mass
Spectrometry Analysis of Peptide Fragments
JNK-IN-2 or JNK-IN-7 treated JNK (25 mg,620 pmol) was dilutedwith ammo-
nium bicarbonate buffer (pH 8.0), then reduced for 30 min at 56C with 10 mMChemistry & Biology 19, 140DTT. After cooling for 5 min, the protein was alkylated with 22.5 mM iodoace-
tamide for 30min at room temperature in the dark, and digested overnight with
1.5 mg of trypsin at 37C. In the morning, 1 mg of Glu-C was added, and the
solution was further incubated at 37C for 8 hr. Digested peptides (2 pmol)
were injected onto a self-packed precolumn (4 cm POROS10R2) and eluted
into the mass spectrometer (LTQ OrbitrapVelos, Thermo Fisher Scientific).
Peptides were subjected to MS2 by CAD (electron multiplier detection, relative
collision energy 35%, q = 0.25) as well as HCD (image current detection, reso-
lution at m/z 400 = 7,500, relative collision energy 35%).
Cell-Based Assays for c-Jun Phosphorylation
The cell-based kinase assays for c-Jun phosphorylation were carried out
by using the LanthaScreen c-Jun (1–79) HeLa cell line (Life Technologies,
Carlsbad, CA, USA) stably express GFP-c-Jun 1–79 and GFP-ATF2 19–106,
respectively. Phosphorylation was determined by measuring the TR-FRET
between a terbium-labeled phospho-c-Jun specific antibody and GFP. The
cells were plated in white tissue culture-treated 384-well plates at a density
of 10,000 cells per well in 32 ml assay medium (Opti-MEM, supplemented
with 0.5% charcoal/dextran-treated FBS, 100 U/ml penicillin, and 100 mg/ml
streptomycin, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate,
25 mM HEPES [pH 7.3], and lacking phenol red). After overnight incubation,
cells were pretreated for 90 min with compound (at indicated concentration)
diluted in 4 ml assay buffer followed by 30 min of stimulation with 5 ng/ml of
TNF-a in 4 ml assay buffer (final assay volume was 40 ml). The medium was
then removed by aspiration, and the cells were lysed by adding 20 ml of lysis
buffer (20 mM Tris-HCl [pH 7.6], 5 mM EDTA, 1% Nonidet P-40 substitute,
5 mM NaF, 150 mM NaCl, and 1:100 protease and phosphatase inhibitor
mix, P8340 and P2850, respectively; Sigma-Aldrich). The lysis buffer included
2 nM of the terbium-labeled anti-c-Jun (pSer73) detection antibodies (Life
Technologies). After allowing the assay to equilibrate for 60 min at room
temperature, TR-FRET emission ratios were determined on a BMG Pherastar
fluorescence plate reader (BMG Labtech, Cary, NC, USA) using the following
parameters: excitation at 340 nm, emission 520 and 490 nm; 100 ms lag time;
200 ms integration time; emission ratio = Em 520/Em 490. All data were
analyzed and plotted using GraphPad Prism 4.
High-Throughput Microscopy
Cells were plated at 7,500 cells/well in 96-well microscopy plates (Corning)
in recommended media for 24 hr and then starved in media lacking serum
for 16 hr. Cells were pretreated for 180 min with 10-fold stock solutions
of JNK inhibitors and for 10 min with control compounds MK2206 (allosteric
Akt inhibitor [Haoyuan Chemexpress]; Hirai et al., 2010), PD0325901 (allosteric
Mek inhibitor [Haoyuan Chemexpress]; Barrett et al., 2008), SB239063 (ATP-
competitive p38 inhibitor [Haoyuan Chemexpress]; Underwood et al., 2000),
KIN001-040 (ATP-competitive JAK1, 2, 3 inhibitor [Haoyuan Chemexpress];
Thompson et al., 2002), and KIN001-208 (IKK inhibitor VIII [Haoyuan Chemex-
press]; Murata et al., 2004) and treated with 10-fold stock solutions of IGF-1,
IL-6, TNF-a (all PeproTech), or anisomycin for 60 min. Cells were fixed in
2% paraformaldehyde for 10 min at room temperature and washed with
PBS-T (PBS, 0.1% Tween 20). Cells were permeabilized in methanol for
10 min at room temperature, washed with PBS-T, and blocked in Odyssey
Blocking Buffer (LI-COR Biosciences) for 1 hr at room temperature. Cells
were incubated overnight at 4C with antibody specific for Erk1/2(pT202/
pY204), Akt(pS473), cJUN(pS73), pP38(T180/Y182), and pSTAT3(Y705) (Cell
Signaling Technology), pRSK1(S380) and pMSK1(S376) (Epitomics), and
NF-kB (Santa Cruz Biotechnology) diluted 1:400 in Odyssey Blocking Buffer.
Cells were washed three times in PBS-T and incubated with rabbit-specific
secondary antibody labeled with Alexa Fluor 647 (Invitrogen) diluted 1:2,000
in Odyssey Blocking Buffer. Cells were washed once in PBS-T, once in
PBS, and incubated in 250 ng/ml Hoechst 33342 (Invitrogen) and 1:1,000
Whole Cell Stain (blue; Thermo Scientific) solution. Cells were washed two
times with PBS and imaged in an imageWoRx high-throughput microscope
(Applied Precision). Data were plotted using DataPflex (Hendriks and Espelin,
2010).
Binding Kinetics Assay
Binding kinetics assay A375 cells (ATCCCRL-1619) were pretreatedwith 1 mM
compound for the indicated amounts of time. Remove the medium and wash–154, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 151
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40, 1% CHAPS, 25 mM Tris, 150 mM NaCl, Phosphatase Inhibitor Cocktail,
Roche 04906845001, and Protease Inhibitor Cocktail, Roche 11836170001).
Rotate end to end for 30 min at 4C. Lysates were cleared by centrifugation
at 14,000 rpm for 15min in the Eppendorf. The cleared lysates were gel filtered
into Kinase Buffer (0.1% NP-40, 20 mM HEPES, 150 mM NaCl, Phosphatase
Inhibitor Cocktail, Protease Inhibitor Cocktail) using Bio-Rad 10DG columns.
The total protein concentration of the gel-filtered lysate should be around
5–15 mg/ml. Cell lysate was labeled with the probe from ActivX at 5 mM for
1 hr. Samples were reduced with DTT, and cysteines were blocked with iodoa-
cetamide and gel filtered to remove excess reagents and exchange the buffer.
Add 1 vol of 23 Binding Buffer (2% Triton-100, 1% NP-40, 2 mM EDTA, 23
PBS) and 50 ml streptavidin bead slurry, and rotate end to end for 2 hr, centri-
fuge at 7,000 rpm for 2 min. Wash three times with 13Binding Buffer and three
times with PBS. Add 30 ml 13 sample buffer to beads; heat samples at 95C for
10 min. Run samples on an SDS-PAGE gel at 110V. After transferred, the
membrane was immunoblotted with JNK antibody (Cell Signaling 9258).
Incubate 1 mMJNK-IN-5with purified JNK3 protein for indicated time period,
then add the ATP-Biotin probe from ActivX at 5 mM for 10 min. Denature the
protein by adding same volume 8 M urea solution and gel filtered to remove
excess reagents and exchange the buffer. Add 1 vol of 23 Binding Buffer
(2% Triton-100, 1% NP-40, 2 mM EDTA, 23 PBS) and 50 ml streptavidin
bead slurry, and rotate end to end for 2 hr, centrifuge at 7,000 rpm for 2 min.
Wash three times with 13 Binding Buffer and three times with PBS. Add
30 ml 13 sample buffer to beads; heat samples at 95C for 10 min. Run
samples on an SDS-PAGE gel at 110V. After transferred, the membrane was
immunoblotted with JNK antibody (Cell Signaling 9252).
Buffers
Lysis Buffer contained 50 mM Tris/HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1%
(w/v) 1 mM sodium orthovanadate, 10 mM sodium b-glycerophosphate,
50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 mM Benzami-
dine, and 2 mM phenylmethanesulphonylfluoride (PMSF) and supplemented
with 1% (v/v) Triton X-100. Kinase assay buffer contained 50 mM Tris/HCl
(pH 7.5) and 0.1 mM EGTA.
Cell Culture, Treatments, and Cell Lysis
HEK293 cells stably expressing Interleukin Receptor 1 (HEK293-IL1R) were
cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented
with 10% FBS, 2 mM glutamine, and 13 antimycotic/antibiotic solution. Cells
were serum starved for 18 hr before incubation with DMSO or different inhib-
itors, stimulated with 2 mM anisomycin (Sigma-Aldrich) for 1 hr, and lysates
were clarified by centrifugation for 10 min at 16,000 3 g and 4C.
Antibodies
Rabbit polyclonal antibodies against total pan JNK isoforms ((#9252),
phospho-pan JNK isoforms (Thr183/Tyr185), (#4668), total p38 (#9212) or
phospho-p38 MAPK (Thr180/Tyr182), (4631 resp.), total c-Jun (#9165), phos-
pho-c-Jun (Ser63), (#9261), and phospho-MSK1 (Ser376) (#9591) were from
Cell Signaling Technology.
SDS-PAGE and Western Blot
Cell lysates (30 mg) were resolved by electrophoresis on SDS polyacrylamide
gels (10%) or Novex 4%–12% gradient gels, and electroblotted to nitro-
cellulose membranes. Membranes were blocked with 5% skimmed milk
(w/v) in 50 mM Tris/HCl (pH 7.5), 0.15 M NaCl, and 0.1% (v/v) Tween (TBST
Buffer). Primary antibodies were used at a concentration of 1 mg/ml, diluted
in 5% skimmilk in TBST, and incubated overnight at 4C. Detection of immune
complexes was performed using horseradish peroxidase-conjugated
secondary antibodies (Pierce) and an enhanced chemiluminescence reagent
(in-house).
JNK2 Kinase Assays
Wild-type JNK2 or mutant JNK2[Cys116Ser] was activated in a reaction
mixture containing 2 mM JNK2, 200 nM MKK4, and 200 nM MKK7 in kinase
assay buffer containing 0.1 mM ATP and 10 mM magnesium chloride. After
incubation at 30 min at 30C, the reaction mixture was snap frozen in aliquots.
Activity of JNK2 was assessed in a total reaction volume of 50 ml containing152 Chemistry & Biology 19, 140–154, January 27, 2012 ª2012 Elsev200 nM activated wild-type JNK or mutant JNK2[Cys116Ser], in kinase buffer
containing 0.1 mM [g-32P]ATP (500–1,000 cpm/pmol), 10 mM magnesium
chloride, and 2 mM ATF2 (residues 19–96) as a substrate. The different
inhibitors, or equivalent DMSO volume in controls, were added immediately
before to the ATP. Reactions were terminated by adding 20 mM EDTA after
30 min at 30C incubation. A total of 40 ml of the reaction mixture was applied
to P81 phosphocellulose paper, whichwas washed in 50mMphosphoric acid,
and phosphorylated ATF2 peptide bound to p81 paper quantified by Cerenkov
counting.
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